Zoetis Inc. $ZTS Shares Sold by Biltmore Family Office LLC

Biltmore Family Office LLC lessened its position in Zoetis Inc. (NYSE:ZTS) by 16.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,368 shares of the company’s stock after selling 277 shares during the period. Biltmore Family Office LLC’s holdings in Zoetis were worth $213,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the first quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the first quarter valued at approximately $29,000. REAP Financial Group LLC raised its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Finally, Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $145.62 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40. The company has a 50 day moving average of $147.88 and a two-hundred day moving average of $153.51. The company has a market cap of $64.53 billion, a P/E ratio of 25.06, a P/E/G ratio of 2.37 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is currently 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research analyst reports. Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. UBS Group dropped their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.